Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2

Toxicol Appl Pharmacol. 2013 Sep 1;271(2):184-95. doi: 10.1016/j.taap.2013.04.021. Epub 2013 May 5.

Abstract

Pulmonary fibrosis (PF) can be a devastating lung disease. It is primarily caused by inflammation leading to severe damage of the alveolar epithelial cells. The pathophysiology of PF is not yet been clearly defined, but studying lung parenchymal injury by involving reactive oxygen species (ROS) through the activation of protease activated receptor-2 (PAR-2) may provide promising results. PAR-2 is a G-protein coupled receptor is known to play an important role in the development of PF. In this study, we investigated the inhibitory role of diallylsulfide (DAS) against ROS mediated activation of PAR-2 and collagen production accompanied by epithelial cell apoptosis. Bleomycin induced ROS levels may prompt to induce the expression of PAR-2 as well as extracellular matrix proteins (ECM), such as MMP 2 and 9, collagen specific proteins HSP-47, α-SMA, and cytokines IL-6, and IL-8RA. Importantly DAS treatment effectively decreased the expression of all these proteins. The inhibitory effect of DAS on profibrotic molecules is mediated by blocking the ROS level. To identify apoptotic signaling as a mediator of PF induction, we performed apoptotic protein expression, DNA fragmentation analysis and ultrastructural details of the lung tissue were performed. DAS treatment restored all these changes to near normalcy. In conclusion, treatment of PF bearing rats with DAS results in amelioration of the ROS production, PAR-2 activation, ECM production, collagen synthesis and alveolar epithelial cell apoptosis during bleomycin induction. We attained the first evidence that treatment of DAS decreases the ROS levels and may provide a potential therapeutic effect attenuating bleomycin induced PF.

Keywords: Apoptosis; BSA; Bleomycin; DAS; Diallylsulfide; ECM; G-protein coupled receptor family; GPCR; HRP; HSP-47; IL-6; IL8RA; MMP2/9; PAR-2; PF; PI; Pulmonary fibrosis; ROS; Reactive oxygen species; TBST; Tris buffered saline-Tween-20; alpha smooth muscle actin; bovine serum albumin; diallylsulfide; extracellular matrix; heat shock protein-47; horseradish peroxidase; interleukin 8 receptor alpha; interleukins-6; matrix metalloproteinases 2 and 9; propidium iodide; protease activated receptor-2; pulmonary fibrosis; reactive oxygen species; α-SMA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allyl Compounds / pharmacology*
  • Animals
  • Antibiotics, Antineoplastic*
  • Antioxidants / pharmacology*
  • Apoptosis / drug effects*
  • Bleomycin*
  • Blotting, Western
  • Collagen / biosynthesis*
  • Coloring Agents
  • Epithelial Cells / drug effects
  • Extracellular Matrix / drug effects
  • Free Radicals / metabolism
  • Immunohistochemistry
  • Male
  • Mast Cells / drug effects
  • Mast Cells / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • Microscopy, Electron, Transmission
  • Microscopy, Fluorescence
  • Pulmonary Alveoli / cytology
  • Pulmonary Alveoli / drug effects
  • Pulmonary Fibrosis / chemically induced
  • Pulmonary Fibrosis / drug therapy*
  • Pulmonary Fibrosis / metabolism
  • Rats
  • Rats, Wistar
  • Real-Time Polymerase Chain Reaction
  • Receptor, PAR-2 / drug effects
  • Receptor, PAR-2 / metabolism*
  • Sulfides / pharmacology*

Substances

  • Allyl Compounds
  • Antibiotics, Antineoplastic
  • Antioxidants
  • Coloring Agents
  • Free Radicals
  • Receptor, PAR-2
  • Sulfides
  • Bleomycin
  • allyl sulfide
  • Collagen
  • Matrix Metalloproteinase 9